StockUnited StatesNasdaqGM

TRVI

Trevi Therapeutics, Inc.

Healthcare · Biotechnology

16.64USD

-0.1800 (-1.07%)

Description Historical Financials Relative Value Research News Discussion OptionsPrice Chart ↗Fundamental Chart ↗

Fiscal Year End12/2025

Last Quarter End06/2026 Q2

Current/T12M(USD)

Issue Data

Last PxUSD / 16.64

P/E—

Dvd Ind Yld—

P/B7.45

P/S—

Curr EV/T12M EBITDA-35.0

Mkt Cap (USD)2.4B

Curr EV (USD)2.1B

Per Share Data

EPS T12M-0.34

DPS—

Bk Val Per Sh2.26

Rev/Sh—

Cash/Sh2.24

Curr Shares Out142.5M

FCF/Sh-0.34

Cash Flow Analysis

P/CF-45.5

Curr P/FCF-45.3

CF/NI1.0

Dvd P/O0.0%

Cash Gen/Cash Reqd—

Csh Dvd Cov—

CFO/Sales—

Eff Interest Rate0.2%

Growth Potential

Dil EPS 1Y Gr31.9%

Cap 1Y Gr83.9%

BPS 1Y Gr39.2%

R&D To Sales—

Retention Rate100.0%

Rev 1Y Gr—

FCF 1Y Gr-10.0%

Assets 1Y Gr74.4%

Profitability

EBITDA-0.1B

EBIT-0.1B

Operating Margin0.0%

Pretax Margin—

Net Margin0.0%

ROA-19.0%

ROE-19.7%

ROC-18.5%

Asset Turnover—

Structure

Current Ratio37.28

Quick Ratio36.68

Debt/Assets0.2%

Debt/Com Eq0.2%

Net Debt/EBITDA0.90

Tot Debt/Capital0.2%

Gross Margin0.0%

EBIT/Int Exp-59,557.0

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.

Reading financial statements from SEC filings…

A first visit to a security takes a few seconds.